GlassScriptPhysician profile
Paul Heraut Pierrot
NPI 1407896053
$1,516.35
in general payments reported to CMS, 2019-2025
26 companies · $633 in 2025
The $633 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $86.41 · 2021: $26.45 · 2022: $74.13 · 2023: $16.12 · 2024: $222 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $870.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $218.43 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $158.49 | 2019-2025 | |
| Novo Nordisk INC | $156.44 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $136.95 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Lilly USA, LLC | $103.97 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $83.64 | 2023-2025 | Shingrix, Bexsero, Trelegy Ellipta |
| Exact Sciences Corporation | $78.44 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $65.71 | 2024-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $58.20 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $57.29 | 2025 | |
| Indivior INC. | $56.68 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $47.10 | 2024-2025 | Lumryz |
| Allergan, INC. | $45.56 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.62 | 2024-2025 | Jardiance, Synjardy |
| Teva Pharmaceuticals USA, INC. | $30.53 | 2019-2025 | Austedo Xr |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $29.84 | 2019-2021 | |
| Eisai INC. | $28.44 | 2019 | |
| Harmony Biosciences LLC | $18.33 | 2025 | |
| Arbor Pharmaceuticals, INC. | $14.85 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.41 | 2019 | |
| Xeris Pharmaceuticals, INC. | $13.94 | 2025 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $13.71 | 2019 | |
| Phathom Pharmaceuticals, INC. | $13.70 | 2025 | Voquezna |
| Kaleo, INC. | $13.28 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.64 | 2019 | |
| Circassia INC. | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Pierrot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.